<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210407050881N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-04</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of fenugreek seed extract on oxidative stress in type 2 diabetic patients</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Fenugreek Seed Extract Supplementation on Blood glucose,Lipid profile, Appetite, Energy Intake and Macronutrient, Oxidative stress in Patients with Type 2 Diabetes:Randomized Double-blind Controlled clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>46</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56128</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Subjects using RAS software (Random allocation software) and randomly, using the method of random blocking (block randomization) in terms of classification on body mass index (25-30 or 35-30 kg / m2) And gender (female or male) and inclusion in the study in the form of 4 groups and blocks with size of 6 , are divided into 2 groups of 23 people, Blinding description: For double-blind research, at the beginning of the study, a set of cans containing the corresponding capsule, which are similar in appearance (color, odor, size, shape), are coded A and B by someone other than the researcher until the researcher is informed. And patients of the type of capsules received by each group.The drug and placebo were similar in characteristics and appearance (color, odor, size).</study_design>
      <phase>3</phase>
      <hc_freetext>Type 2 diabetes mellitus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Dry extract of fenugreek seeds of Barij Essential Oil Company called "Glucorx B" (containing 46.4 micrograms of luteolin per tablet) will be consumed in the form of three 335 mg tablets. The study population in this study is people with type 2 diabetes who need to receive diet and nutritional advice due to ethical considerations. According to the available reference (Krause), the prescribed regimen should be appropriate to the clinical condition of each patient; Therefore, the amount of reduction in calories per person will not be a fixed amount. To calculate calories, BMR (using the Myfeline formula) will be multiplied by physical activity and TEF. People in this group are on a diabetic and calorie-restricted diet for 8 weeks. The relevant food menu will be taught to patients along with nutritional recommendations. Intervention 2: Control group: will consume three 335 mg placebo tablets made of microcrystalline cellulose prepared by Barij Essential Oil Company. The study population in this study is people with type 2 diabetes who need to receive diet and nutritional advice due to ethical considerations. According to the available reference (Krause), the prescribed regimen should be appropriate to the clinical condition of each patient; Therefore, the amount of reduction in calories per person will not be a fixed amount. To calculate calories, BMR (using the Myfeline formula) will be multiplied by physical activity and TEF. People in this group are on a diabetic and calorie-restricted diet for 8 weeks. The relevant food menu will be taught to patients along with nutritional recommendations.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Chehregosha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nutrition - Tabriz University of Medical Sciences - Golgasht St. - Attar Neyshabouri St. - Tabriz - Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3335 5921</telephone>
        <email>fatemehchehregosha4@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Chehregosha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nutrition - Tabriz University of Medical Sciences - Golgasht St. - Attar Neyshabouri St. - Tabriz - Iran</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166616471</zip>
        <telephone>+98 41 3335 5921</telephone>
        <email>fatemehchehregosha4@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients in the age range of 30-65 years
Having at least 6 months of diabetes history (according to criteria of American Diabetes Association)
BMI between 25 and 35
Taking blood sugar lowering drugs
No herbs at least 3 months before the study to be used routinely
Willingness to participate in the project</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy or breastfeeding or its intention
Kidney, liver, gastrointestinal, thyroid, and rheumatic diseases
Allergy to plants of the Fabaceae family</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Dry extract of fenugreek seeds of Barij Essential Oil Company called "Glucorx B" (containing 46.4 micrograms of luteolin per tablet) will be consumed in the form of three 335 mg tablets. The study population in this study is people with type 2 diabetes who need to receive diet and nutritional advice due to ethical considerations. According to the available reference (Krause), the prescribed regimen should be appropriate to the clinical condition of each patient; Therefore, the amount of reduction in calories per person will not be a fixed amount. To calculate calories, BMR (using the Myfeline formula) will be multiplied by physical activity and TEF. People in this group are on a diabetic and calorie-restricted diet for 8 weeks. The relevant food menu will be taught to patients along with nutritional recommendations.</i_keyword>
      <i_keyword>Control group: will consume three 335 mg placebo tablets made of microcrystalline cellulose prepared by Barij Essential Oil Company. The study population in this study is people with type 2 diabetes who need to receive diet and nutritional advice due to ethical considerations. According to the available reference (Krause), the prescribed regimen should be appropriate to the clinical condition of each patient; Therefore, the amount of reduction in calories per person will not be a fixed amount. To calculate calories, BMR (using the Myfeline formula) will be multiplied by physical activity and TEF. People in this group are on a diabetic and calorie-restricted diet for 8 weeks. The relevant food menu will be taught to patients along with nutritional recommendations.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fasting blood suger. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Measurement of blood levels using electrochemical methods.</prim_outcome>
      <prim_outcome>Serum insulin. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Measurement of serum level by ELISA kit.</prim_outcome>
      <prim_outcome>Insulin resistance. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Formula calculation.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Measurement of serum level using spectrophotometric method.</prim_outcome>
      <prim_outcome>LDL. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Friedwald Computational Method.</prim_outcome>
      <prim_outcome>HDL. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Measurement of serum level using spectrophotometric method.</prim_outcome>
      <prim_outcome>Total cholestrol. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Measurement of serum level using spectrophotometric method.</prim_outcome>
      <prim_outcome>PAB. Timepoint: Before intervention and 2 months after intervention. Method of measurement: Measurement of serum level by ELISA kit.</prim_outcome>
      <prim_outcome>Appetite. Timepoint: Before intervention and 2 months after intervention. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Calorie intake. Timepoint: Before intervention and 2 months after intervention. Method of measurement: questionnaire(Finally, energy calculation using n4 software).</prim_outcome>
      <prim_outcome>Macronutrients intake. Timepoint: Before intervention and 2 months after intervention. Method of measurement: n4 software.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-08-02</approval_date>
        <contact_name>Ethics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Factulty of Nutrition, Tabriz University of Medical Sciences, Golgasht St, Attar Neyshabouri St., Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
